Vir Biotechnology, Inc. Announces That Johanna Friedl-Naderer, the Company?s Executive Vice President and Chief Operating Officer, Will Be Leaving the Company on September 29, 2023
September 20, 2023 at 06:02 am
Share
On September 20, 2023, Vir Biotechnology, Inc. announced that Johanna Friedl-Naderer, the Company?s Executive Vice President and Chief Operating Officer, will be leaving the Company on September 29, 2023. The Company does not intend to fill the Chief Operating Officer role, and Mrs. Friedl-Naderer?s responsibilities will be overseen by other members of the Company?s management team.
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Vir Biotechnology, Inc. Announces That Johanna Friedl-Naderer, the Company?s Executive Vice President and Chief Operating Officer, Will Be Leaving the Company on September 29, 2023
VIR BIOTECHNOLOGY, INC. 
